Design, synthesis and computational study of new benzofuran hybrids as dual PI3K/VEGFR2 inhibitors targeting cancer.

ABSTRACT: Design and synthesis of a new series of benzofuran derivatives has been performed. ¹H-NMR, ¹³C-NMR, elemental analysis, and IR were used to confirm the structures of the produced compounds. Hepatocellular carcinoma (HePG2), mammary gland breast cancer (MCF-7), epithelioid carcinoma cervical cancer (Hela), and human prostate cancer are used to test anticancer activity (PC3). In compared to DOX (4.17-8.87 µM), Compound 8 demonstrated the highest activity against HePG and PC3 cell lines, with an IC₅₀ range of 11-17 µM. Compound 8 inhibited PI3K and VEGFR-2 with IC₅₀ values of 2.21 and 68 nM, respectively, compared to 6.18 nM for compound LY294002 and 31.2 nM for compound sorafenib as PI3K and VEGFR-2 reference inhibitors, selectively. The molecular

SUBMITTER: El-Khouly OA 

PROVIDER: S-EPMC9556824 | biostudies-literature | 2022 Oct

REPOSITORIES: biostudies-literature